TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$34.08
1.01 (3.05%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Jan 28, 2026
0d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.99
Based on 8.1% avg growth
INTRINSIC VALUE TODAY
$32.90
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $34.08, which is considered extended relative to its 30-day fair value range of $31.29 to $32.75. The stock's valuation (Forward PE: 10.6) is in line with its historical norms (11.6). Remarkably, the market is currently pricing in an annual earnings decline of 2.9% over the next few years. This pessimistic expectation contrasts with the company's recent 40.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TEVA is in a strong uptrend. The price is approaching resistance at $33.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TEVA is in a strong uptrend. The price is approaching resistance at $33.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$31.29 -
$32.75
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.0%
Protect Your Profits
TEVA is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- NEUTRAL: Near Wall St target ($35.32)
Fair Price Analysis
30-Day Fair Range
$31.29 -
$32.75
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$30.70
Resistance Level
$33.64
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
10.64
Wall Street Target
$35.32
(+6.8%)
Revenue Growth (YoY)
11.4%
Earnings Growth (YoY)
40.0%
Profit Margin
8.2%
Valuation Discount vs History
-2.9% cheaper
PE vs Historical
10.6 vs 11.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.9%
(market-implied from PE analysis)
1-Year Target
$32.11
(-3%)
2-Year Target
$31.18
(-6%)
3-Year Target
$30.28
(-9%)
3-Yr Target (if PE normalizes)
(PE: 11→12)
$33.00
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 12.1%)
$97.74
(+196%)
Base:
(SPY PE: 10.6, Growth: 12.1%)
$46.65
(+41%)
Bear:
(PE: 9.0, Growth: 12.1%)
$39.65
(+20%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 27.45 | Current EPS (TTM): $1.21
Bull Case
$73.06
(+114%)
Analyst growth 100.0%, PE expands to 30.2
Base Case
$66.42
(+95%)
Market implied 100.0%, PE stable at 27.5
Bear Case
$22.58
(-34%)
Severe decline -20.0%, PE contracts to 23.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.6 to 11.6
Stabilization Target:
$36.04
(+9.0%)
PE Expansion Potential:
+9.0%
Last updated: January 30, 2026 9:45 PM ET
Data refreshes hourly during market hours. Next update: 10:45 PM
Data refreshes hourly during market hours. Next update: 10:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced TEVA Option Strategies
Professional options setups generated by AI based on today's TEVA price and gamma walls.
